Cargando…

Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma

BACKGROUND: Chemoradiotherapy alone is the standard treatment for locally advanced squamous cell anal carcinoma (SCAC). However, up to 50% of patients will experience recurrence; thus, there is a need for new treatments to improve outcomes. Modified docetaxel, cisplatin and 5-fluorouracil (mDCF) is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Stefano, Boustani, Jihane, Vernerey, Dewi, Vendrely, Véronique, Evesque, Ludovic, Francois, Eric, Quero, Laurent, Ghiringhelli, Francois, de la Fouchardière, Christelle, Dahan, Laëtitia, Bouché, Oliver, Chibaudel, Benoist, Hajbi, Farid El, Vernet, Chloé, Rebucci-Peixoto, Magali, Feuersinger, Alexandra, Maritaz, Christophe, Borg, Christophe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472525/ https://www.ncbi.nlm.nih.gov/pubmed/36119522 http://dx.doi.org/10.3389/fonc.2022.918499

Ejemplares similares

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial
por: Kim, Stefano, et al.
Publicado: (2020)

The Comparison of mDCF and mFOLFOX-6 as First-Line Treatment in Metastatic Gastric Cancer
por: Acikgoz, Yusuf, et al.
Publicado: (2021)

DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study
por: Kim, Stefano, et al.
Publicado: (2023)

Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses
por: Zettl, Markus, et al.
Publicado: (2022)

Modified DCF (Docetaxel, Cisplatin and 5-fluorouracil) chemotherapy is effective for the treatment of advanced rectal squamous cell carcinoma
por: Hervé, Laure, et al.
Publicado: (2022)

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)
por: Kim, Stefano, et al.
Publicado: (2017)

Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial
por: Ochenduszko, Sebastian, et al.
Publicado: (2015)

Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma
por: Kim, Stefano, et al.
Publicado: (2020)

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study
por: Cohen, Romain, et al.
Publicado: (2020)

Anti-Telomerase CD4(+) Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials
por: Spehner, Laurie, et al.
Publicado: (2020)

A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T(H)1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study
por: Rebucci-Peixoto, Magali, et al.
Publicado: (2022)

"Displasia coxo femoral (DCF) en el perro" /
por: Ocaña de la Rosa, Delhy
Publicado: (2009)

Radiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer
por: Boustani, Jihane, et al.
Publicado: (2020)

An analytic model for Throughput Optimal Distributed Coordination Function (TO-DCF)
por: Fitzgerald, Emma, et al.
Publicado: (2017)

Dcf1 induces glioblastoma cells apoptosis by blocking autophagy
por: Luo, Guanghong, et al.
Publicado: (2021)

Proof-of-concept study of the efficacy of a microbiota-directed complementary food formulation (MDCF) for treating moderate acute malnutrition
por: Mostafa, Ishita, et al.
Publicado: (2020)

Dcf1 Deficiency Attenuates the Role of Activated Microglia During Neuroinflammation
por: Wang, Jiao, et al.
Publicado: (2018)

High-dose thiotepa-related neurotoxicity and the role of tramadol in children
por: Maritaz, Christophe, et al.
Publicado: (2018)

Successful treatment with DCF chemotherapy and radiotherapy for primary squamous cell carcinoma of the prostate
por: Atagi, Kaya, et al.
Publicado: (2021)

A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial
por: Bachet, Jean-Baptiste, et al.
Publicado: (2015)

Overexpression of DCF1 inhibits glioma through destruction of mitochondria and activation of apoptosis pathway
por: Xie, Yuqiong, et al.
Publicado: (2014)

Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer
por: Dong, Lei, et al.
Publicado: (2014)

Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma
por: GÜRLER, Fatih, et al.
Publicado: (2022)

FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer
por: Carola, Candice, et al.
Publicado: (2018)

Developing shelf-stable Microbiota Directed Complementary Food (MDCF) prototypes for malnourished children: study protocol for a randomized, single-blinded, clinical study
por: Mostafa, Ishita, et al.
Publicado: (2022)

Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin—folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial
por: Messager, Mathieu, et al.
Publicado: (2016)

DCF intraperitoneal and intravenous dual chemotherapy regimen for advanced gastric cancer: A feasibility study
por: FENG, ZENG-LI, et al.
Publicado: (2015)

Comparison the Incidence and Severity of Side Effects Profile Of FOLFOX and DCF Regimens in Gastric Cancer Patients
por: Salehifar, Ebrahim, et al.
Publicado: (2019)

Impact of preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree of malignant esophageal stenosis
por: Yamaguchi, Takahisa, et al.
Publicado: (2023)

Primary Linitis Plastica of the Rectum: Focus on Magnetic Resonance Imaging Patterns and Treatment Options
por: Boustani, Jihane, et al.
Publicado: (2015)

Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)
por: Vernerey, Dewi, et al.
Publicado: (2016)

Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?
por: Maritaz, Christophe, et al.
Publicado: (2022)

FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer
por: Adenis, Antoine, et al.
Publicado: (2021)

Present and Future Research on Anal Squamous Cell Carcinoma
por: Spehner, Laurie, et al.
Publicado: (2021)

The efficacy and adverse reactions of DCF and FOLFOXs regimens for patients with advanced gastric cancer in China: a meta-analysis
por: Chen, Minxue, et al.
Publicado: (2020)

Synthesis and Evaluation of the Antioxidant Activity of Lipophilic Phenethyl Trifluoroacetate Esters by In Vitro ABTS, DPPH and in Cell-Culture DCF Assays
por: Bernini, Roberta, et al.
Publicado: (2018)

Velocity-Adaptive V2I Fair-Access Scheme Based on IEEE 802.11 DCF for Platooning Vehicles
por: Wu, Qiong, et al.
Publicado: (2018)

Pyrocatalysis—The DCF assay as a pH-robust tool to determine the oxidation capability of thermally excited pyroelectric powders
por: Raufeisen, Sascha, et al.
Publicado: (2020)

Cetuximab-induced aseptic meningitis: case report and review of a rare adverse event
por: Maritaz, Christophe, et al.
Publicado: (2016)

Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?
por: Anota, Amélie, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_sg4jg77j1tcvno9qs8lc8cah0c